Please try another search
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Richard Marsden | 53 | 2004 | CEO, MD & Executive Director |
Simon James Blouet Shaw | 56 | 2003 | Non-Executive Chairman |
Stephen T. Holgate | 73 | 2003 | Co-Founder, Non-Executive Director & Member of Scientific Advisory Board |
Donna Davies | - | - | Co-Founder & Member of Scientific Advisory Board |
Ratko Djukanovic | - | - | Co-Founder & Member of Scientific Advisory Board |
David Bruce Campbell | 78 | 2006 | Non-Executive Director & Member of Scientific Advisory Board |
Phillip David Monk | 54 | 2009 | Chairman of Scientific Advisory Board, Chief Scientific Officer & Executive Director |
Amanda Dawn Radford | 53 | 2022 | Independent Non-Executive Director |
Felicity Jane Gabbay | 71 | 2022 | Member of Scientific Advisory Board & Independent Non-Executive Director |
Joseph Tregonning Colliver | 43 | 2023 | CFO & Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review